Furthermore, based on the closed correlation between excessive fructose intake, insulin resistance, and NAFLD, several studies indicated that metformin, an AMPK activator, might have therapeutic potential on liver steatosis [30]. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.